Skip to content

Author

Lawrence M. Blatt

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

ALG-055009 in non-cirrhotic adults with metabolic dysfunction-associated steatohepatitis (HERALD): a randomised, double-blind, placebo-controlled, phase 2a trial.

BACKGROUND Thyroid hormone receptor β (THR-β) agonists reduce atherogenic lipids, hepatic fat, and improve histology in metabolic dysfunction-associated steatohepatitis (MASH). The phase 2a HERALD study evaluated the efficacy, safety, pharmacokinetics, and pharmacodynamics of the selective and potent THR-β agonist ALG-...

R. Loomba, Stanley Wang, Dimple Desai et al. · 0 citations
Aug 2026

Antiviral profile of hepatitis B virus capsid assembly modulator ALG-001075, the parent of pevifoscorvir sodium.

Chronic hepatitis B virus (HBV) infection remains an important unmet medical need with 240 million patients worldwide. The HBV capsid assembly process has emerged as a key target for more efficient antiviral intervention. Pevifoscorvir sodium (ALG-000184), an oral prodrug of the potent HBV capsid assembly modulator (CA...

Y. Debing, Hannah Vanrusselt, Cheng Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.